On November 17, 2015 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will present eight posters at the 2015 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 8 to 12, 2015 in San Antonio, Texas (Press release, Myriad Genetics, NOV 17, 2015, View Source [SID:1234508272]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Myriad is committed to bringing transformative molecular diagnostics to people with cancer. Our data at SABCS showcase our expanding portfolio of companion diagnostics and their potential to help personalize treatments for people with breast cancer," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories. "We’re also excited about several new studies that highlight the ability of our myRisk Hereditary Cancer test to identify patients at risk for hereditary cancers."

A list of the Myriad presentations at SABCS is below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS15.

myChoice HRD Poster Presentations

Title: The role of germline BRCA status and Homologous Recombination Deficiency and response to neoadjuvant weekly paclitaxel followed by anthracycline-based chemotherapy.
Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P3-07-29.

Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer.
Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P3-07-13.

Title: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC); A pooled analysis.
Date: Thursday, Dec. 10, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P3-07-12.
myRisk Hereditary Cancer Poster Presentations

Title: Predisposing germline mutations in an unselected academic breast cancer (BC) cohort.
Date: Wednesday, Dec. 9, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster P1-08-07.

Title: The patient experience in a prospective trial of multiple-gene panel testing for cancer risk.
Date: Thursday, Dec. 10, 2015: 7:30 to 9:00 a.m. CT.
Location: Poster P2-09-07.

Title: Interim analysis of multiplex gene panel testing for inherited susceptibility to breast cancer.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-01.

Title: Multiplex Identification of genetic etiologies among women with bilateral breast cancer using a 25-gene hereditary cancer panel.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-02.

Title: Characterization of Li-Fraumeni syndrome diagnosed using a 25-gene hereditary cancer panel.
Date: Friday, Dec. 11, 2015: 5:00 to 7:00 p.m. CT.
Location: Poster Discussion PD7-03.

For more information about these presentations, please visit the SABCS website at View Source